◎ Sugi Atlas

Atlas / Drug / Cannabinol

Cannabinol

drug
On this page

Also known as NSC-134455SID144207035

Summary

Cannabinol (CHEMBL74415) is a phase-3 clinical-stage small molecule targeting TRPV2, CNR1, and SCN9A; indicated across 54 conditions including epilepsy and cannabis dependence.

At a glance

  • Status: Max clinical phase 3 (not approved)
  • Modality: Small molecule
  • Targets: 4 (TRPV2, CNR1, SCN9A…)
  • Indications: 54 conditions
  • Clinical trials: 3
  • Chemistry: 310.4 Da · C21H26O2

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL74415
NameCannabinol
TypeSmall molecule
Max phase3
FDA approvedno
PubChem CID2543
Molecular formulaC21H26O2
Molecular weight310.4
InChIKeyVBGLYOIFKLUMQG-UHFFFAOYSA-N

SMILES: CCCCCC1=CC(=C2C(=C1)OC(C3=C2C=C(C=C3)C)(C)C)O

IUPAC name: 6,6,9-trimethyl-3-pentylbenzo[c]chromen-1-ol

Also known as: Cannabinol, NSC-134455, cannabinol, SID144207035, CANNABINOL

Patent coverage: 7,483 distinct patent families (18,794 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 13,607 (72%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
TRPV2TRPV2Activation4.111.4%Q9Y5S1
CNR1CB1 receptorPartial agonist6.50%P21554
SCN9ANav1.74.520%Q15858
SCN10ANav1.84.80.1%Q9Y5Y9

Broader ChEMBL bioactivity targets: 22 (assay-derived). Sample: Cannabinoid receptor 1, Sodium-dependent noradrenaline transporter, Cytochrome P450 1A1, 5-hydroxytryptamine receptor 2A, Sodium-dependent serotonin transporter, Mu-type opioid receptor, Cannabinoid receptor 2, Transient receptor potential cation channel subfamily V member 4, Transient receptor potential cation channel subfamily V member 2, Transient receptor potential cation channel subfamily V member 4.

Bioactivity

ChEMBL activities: 36 potent at pChembl ≥ 5 of 45 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
CNR17.89Ki13nMCHEMBL_ACT_19371455
CNR27.8Ki16nMCHEMBL_ACT_19371449
CNR17.16Ki70nMCHEMBL_ACT_24661757
CNR27.16Ki70nMCHEMBL_ACT_24661758
CNR27.14EC5073nMCHEMBL_ACT_18373337
CNR17.12EC5075nMCHEMBL_ACT_18373335
CYP1A27.1Ki79nMCHEMBL_ACT_18157612
CNR27.02Ki96nMCHEMBL_ACT_834084
CNR17Ki100nMCHEMBL_ACT_29092151
P202726.92EC50120nMCHEMBL_ACT_685007
CNR26.9Ki126.4nMCHEMBL_ACT_685006
CYP1B16.83Ki148nMCHEMBL_ACT_18157613
Q6RI866.75EC50180nMCHEMBL_ACT_18373339
TRPA16.75EC50180nMCHEMBL_ACT_24661715
Q8R4556.68IC50210nMCHEMBL_ACT_18373341
TRPA16.68IC50210nMCHEMBL_ACT_24661731
P202726.67Ki211.2nMCHEMBL_ACT_685005
CNR26.58EC50261.2nMCHEMBL_ACT_685008
CNR26.52Ki300nMCHEMBL_ACT_24661759
CNR16.51Ki308nMCHEMBL_ACT_834083
P202726.5EC50316.2nMCHEMBL_ACT_1670400
P202726.41Ki392.2nMCHEMBL_ACT_685004
TRPA16.4IC50400nMCHEMBL_ACT_24661727
CYP1A16.27Ki541nMCHEMBL_ACT_18157611
CYP2A66Ki1000nMCHEMBL_ACT_24661764
CNR15.96Ki1100nMCHEMBL_ACT_24661756
SLC6A25.94IC501150nMCHEMBL_ACT_29082026
CYP2B65.59Ki2550nMCHEMBL_ACT_24661766
OPRM15.49IC503210nMCHEMBL_ACT_29082022
SLC6A45.47IC503350nMCHEMBL_ACT_29082030

Target pathways

Aggregated over 4 target gene(s): TRPV2, CNR1, SCN9A, SCN10A.

Top Reactome pathways

14 total, by targets touching each:

PathwayTargetsGenes
Developmental Biology2SCN10A, SCN9A
L1CAM interactions2SCN10A, SCN9A
Muscle contraction2SCN10A, SCN9A
Axon guidance2SCN10A, SCN9A
Interaction between L1 and Ankyrins2SCN10A, SCN9A
Cardiac conduction2SCN10A, SCN9A
Phase 0 - rapid depolarisation2SCN10A, SCN9A
Nervous system development2SCN10A, SCN9A
TRP channels1TRPV2
Class A/1 (Rhodopsin-like receptors)1CNR1
G alpha (i) signalling events1CNR1
Sensory Perception1SCN9A
Sensory perception of taste1SCN9A
Sensory perception of sweet, bitter, and umami (glutamate) taste1SCN9A

Dominant GO biological processes

GO termTargets
monoatomic ion transport3
monoatomic ion transmembrane transport3
transmembrane transport3
sensory perception2
sodium ion transmembrane transport2
cardiac muscle cell action potential involved in contraction2
regulation of heart rate2
sodium ion transport2
monoatomic cation transmembrane transport2
response to temperature stimulus1
positive regulation of axon extension1
calcium ion transmembrane transport1
positive regulation of calcium ion import1
calcium ion import across plasma membrane1
positive regulation of cold-induced thermogenesis1

Indications & clinical

Indications

54 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
epilepsy3MONDO:0005027EFO:0000474
cannabis dependence3MONDO:0005689EFO:0007191
marasmus3MONDO:0006848EFO:1001033
autism spectrum disorder3MONDO:0005258EFO:0003756
Crohn disease2MONDO:0005011EFO:0000384
ulcerative colitis2MONDO:0005101EFO:0000729
Tourette syndrome2MONDO:0007661EFO:0004895
spinal cord injury2MONDO:0043797EFO:1001919
psoriatic arthritis2MONDO:0011849EFO:0003778
osteoarthritis, knee2MONDO:0005416EFO:0004616
complex regional pain syndrome2MONDO:0019369EFO:1001998
severe acute respiratory syndrome2MONDO:0005091EFO:0000694
AIDS2MONDO:0012268EFO:0000765
post-traumatic stress disorder2MONDO:0005146EFO:0001358
hepatitis C virus infection2MONDO:0005231EFO:0003047
autism2MONDO:0005260EFO:0003758
insomnia2MONDO:0013600EFO:0004698
anxiety2MONDO:0011918EFO:0005230
opiate dependence2MONDO:0005530EFO:0005611
fibromyalgia2MONDO:0005546EFO:0005687
visual epilepsy2MONDO:0001386HP:0001250
depressive disorder2MONDO:0002050MONDO:0002050
brain injury2MONDO:0043510MONDO:0043510
hidradenitis suppurativa2MONDO:0006559EFO:1000710
dementia2MONDO:0001627HP:0000726
amyotrophic lateral sclerosis2MONDO:0004976MONDO:0004976
Parkinson disease2MONDO:0005180MONDO:0005180
multiple sclerosis2MONDO:0005301MONDO:0005301
Huntington disease2MONDO:0007739MONDO:0007739
sickle cell disease2MONDO:0011382MONDO:0011382
childhood malignant neoplasm2MONDO:0006517EFO:1000654
bipolar disorder2MONDO:0004985MONDO:0004985
neoplasm2MONDO:0005070MONDO:0004992
glaucoma2MONDO:0005041MONDO:0005041
rheumatoid arthritis2MONDO:0008383EFO:0000685
obesity disorder2MONDO:0011122EFO:0001073
neuralgia1MONDO:0021667EFO:0005762
diabetic neuropathy1MONDO:0006626EFO:1000783
glioblastoma1MONDO:0018177EFO:0000519
obsessive-compulsive disorder1MONDO:0008114EFO:0004242
migraine disorder1MONDO:0005277MONDO:0005277
carcinoma1MONDO:0004993EFO:0000313

12 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 3.

Phase distribution

PhaseTrials
PHASE2/PHASE31
PHASE1/PHASE21
Not specified1

Top trials by phase / activity

NCTPhaseStatusTitle
NCT03675971PHASE2/PHASE3UNKNOWNCOPE: Cannabinoids to Obviate Pain Experiment After Knee Replacement
NCT05344170PHASE1/PHASE2COMPLETEDCannabinol Use in Patients With Insomnia Disorder
NCT05212402Not specifiedCOMPLETEDAssessing the Effects of a Cannabidiol Derived From Hemp Supplement in Healthy Adults

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

151 molecules share ≥1 primary target. Top 60 by shared-target count:

MoleculeSourceStatusShared targets
CannabidiolChEMBL + PubChemPhase 4 (approved)CNR1, SCN9A, TRPV2
IMIPRAMINEChEMBL + PubChemPhase 4 (approved)CNR1, SCN10A, SCN9A
SERTINDOLEChEMBLPhase 4 (approved)CNR1, SCN10A, SCN9A
NITRENDIPINEChEMBLPhase 3CNR1, SCN10A, SCN9A
AMIODARONEChEMBL + PubChemPhase 4 (approved)SCN10A, SCN9A
AMITRIPTYLINEChEMBL + PubChemPhase 4 (approved)SCN10A, SCN9A
CHLORPROMAZINEChEMBL + PubChemPhase 4 (approved)SCN10A, SCN9A
DILTIAZEMChEMBL + PubChemPhase 4 (approved)SCN10A, SCN9A
HALOPERIDOLChEMBL + PubChemPhase 4 (approved)SCN10A, SCN9A
LAMOTRIGINEChEMBL + PubChemPhase 4 (approved)SCN10A, SCN9A
MEXILETINEChEMBL + PubChemPhase 4 (approved)SCN10A, SCN9A
NIFEDIPINEChEMBL + PubChemPhase 4 (approved)SCN10A, SCN9A
PIMOZIDEChEMBL + PubChemPhase 4 (approved)SCN10A, SCN9A
MIBEFRADILChEMBLPhase 4 (approved)SCN10A, SCN9A
TETRACAINEChEMBLPhase 4 (approved)CNR1, SCN9A
AJMALINEChEMBLPhase 3SCN10A, SCN9A
ELECLAZINEChEMBLPhase 3SCN10A, SCN9A
TEDISAMILChEMBLPhase 3SCN10A, SCN9A
VIXOTRIGINEChEMBLPhase 3SCN10A, SCN9A
CANNABIDIVARINChEMBLPhase 2CNR1, TRPV2
CANNABIGEROLChEMBLPhase 2CNR1, TRPV2
CIFENLINEChEMBLPhase 2SCN10A, SCN9A
FUNAPIDEChEMBLPhase 2SCN10A, SCN9A
PF-04531083ChEMBLPhase 2SCN10A, SCN9A
TETRAHYDROCANNABIVARINChEMBLPhase 2CNR1, TRPV2
SAFINAMIDEChEMBL + PubChemPhase 4 (approved)SCN9A
TAFAMIDISChEMBL + PubChemPhase 4 (approved)CNR1
ACARBOSEChEMBLPhase 4 (approved)CNR1
ALCLOMETASONE DIPROPIONATEChEMBLPhase 4 (approved)CNR1
ALPRAZOLAMChEMBLPhase 4 (approved)CNR1
AMCINONIDEChEMBLPhase 4 (approved)CNR1
AMPRENAVIRChEMBLPhase 4 (approved)CNR1
ATENOLOLChEMBLPhase 4 (approved)CNR1
BECLOMETHASONE DIPROPIONATEChEMBLPhase 4 (approved)CNR1
BEPRIDILChEMBLPhase 4 (approved)CNR1
BIFONAZOLEChEMBLPhase 4 (approved)CNR1
BUCLIZINEChEMBLPhase 4 (approved)CNR1
BUSPIRONEChEMBLPhase 4 (approved)CNR1
CAFFEINEChEMBLPhase 4 (approved)CNR1
CALCITRIOLChEMBLPhase 4 (approved)CNR1
CANDESARTAN CILEXETILChEMBLPhase 4 (approved)CNR1
CARBAMAZEPINEChEMBLPhase 4 (approved)SCN9A
CARBENOXOLONEChEMBLPhase 4 (approved)CNR1
CEFDINIRChEMBLPhase 4 (approved)CNR1
CHLORHEXIDINEChEMBLPhase 4 (approved)CNR1
CICLESONIDEChEMBLPhase 4 (approved)CNR1
DEXAMETHASONEChEMBLPhase 4 (approved)CNR1
DRONABINOLChEMBLPhase 4 (approved)CNR1
ECONAZOLEChEMBLPhase 4 (approved)CNR1
EFAVIRENZChEMBLPhase 4 (approved)CNR1
ENZALUTAMIDEChEMBLPhase 4 (approved)CNR1
ERYTHROMYCINChEMBLPhase 4 (approved)CNR1
ETHAMBUTOLChEMBLPhase 4 (approved)CNR1
FELODIPINEChEMBLPhase 4 (approved)CNR1
FENOFIBRATEChEMBLPhase 4 (approved)CNR1
FENTICONAZOLEChEMBLPhase 4 (approved)CNR1
FEXOFENADINEChEMBLPhase 4 (approved)CNR1
FLUOXETINEChEMBLPhase 4 (approved)CNR1
FLUSPIRILENEChEMBLPhase 4 (approved)CNR1
FLUTICASONE FUROATEChEMBLPhase 4 (approved)CNR1

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot